Renfeng Guo
Founder en INFLARX N.V. .
Fortuna: 3 M $ al 31/03/2024
Perfil
Renfeng Guo founded InflaRx GmbH in 2007, where he worked as Chief Scientific Officer from 2009 to 2012 and InflaRx NV in 2007, where he is working as Executive Director & Chief Scientific Officer from 2007.
Dr. Guo also formerly worked at the University of Michigan, as Associate Professor.
Dr. Guo received his doctorate degree from Norman Bethune Medical University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
INFLARX N.V.
2.99% | 31/12/2023 | 1 762 144 ( 2.99% ) | 3 M $ | 31/03/2024 |
Cargos activos de Renfeng Guo
| Empresas | Cargo | Inicio |
|---|---|---|
| INFLARX N.V. | Founder | 01/12/2007 |
Antiguos cargos conocidos de Renfeng Guo.
| Empresas | Cargo | Fin |
|---|---|---|
| University of Michigan | Corporate Officer/Principal | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Founder | - |
Formación de Renfeng Guo.
| Norman Bethune Medical University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| INFLARX N.V. | Health Technology |
| Empresas privadas | 1 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Renfeng Guo
